Compare · DXCM vs STVN
DXCM vs STVN
Side-by-side comparison of DexCom Inc. (DXCM) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 4.8x STVN ($4.90B).
- Over the past year, DXCM is down 13.5% and STVN is down 24.5% - DXCM leads by 11.0 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 1 for STVN).
- DXCM has more recent analyst coverage (25 ratings vs 20 for STVN).
- Company
- DexCom Inc.
- Stevanato Group S.p.A.
- Price
- $61.55-1.84%
- $16.22-0.12%
- Market cap
- $23.76B
- $4.90B
- 1M return
- -7.89%
- +13.82%
- 1Y return
- -13.51%
- -24.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2021
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 20
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest STVN
- Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form 3 filed by new insider Santel Luciano
- SEC Form 3 filed by new insider Magistretti Elisabetta
- SEC Form 3 filed by new insider Flynn Karen
- SEC Form 3 filed by new insider Federici William J
- SEC Form 3 filed by new insider Spinazzi Alvise
- SEC Form 3 filed by new insider Morel Donald E Jr
- SEC Form 3 filed by new insider Stevanato Franco
- Amendment: SEC Form 3 filed by new insider Stevanato Sergio
- SEC Form 3 filed by new insider Lin Sue-Jean